 Connection
Katherine Tzou to Humans
This is a "connection" page, showing publications Katherine Tzou has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.076 |
|
|
|
-
Malouff TD, Stross WC, Seneviratne DS, Waddle MR, May BC, Buskirk SJ, Tzou KS. Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis. Prostate Cancer Prostatic Dis. 2020 06; 23(2):349-355.
Score: 0.016
-
Tzou K, Tan WW, Buskirk S. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy. Expert Rev Anticancer Ther. 2011 Jan; 11(1):125-36.
Score: 0.009
-
Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E, Kendi AT, Tzou K, Quevedo F, Choo R, Moore CN, Ho TH, Singh P, Keole SR, Wong WW, Sartor O, Bryce AH. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. Prostate. 2022 09; 82(12):1202-1209.
Score: 0.005
-
Shaw P, Raymond G, Tzou KS, Baxi S, Mani RR, Kumar Govind S, Chandramoorthy HC, Sivanandy P, Rajagopal M, Samiappan S, Krishnan S, Jayaraj R. Molecular Investigation of miRNA Biomarkers as Chemoresistance Regulators in Melanoma: A Protocol for Systematic Review and Meta-Analysis. Genes (Basel). 2022 01 08; 13(1).
Score: 0.005
-
Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 12; 17(12):1529-1554.
Score: 0.004
-
Leon J, Trifiletti DM, Waddle MR, Vallow L, Ko S, May B, Tzou K, Ruiz-Garcia H, Lundy L, Chaichana K, Vibhute P, Peterson JL. Trends in the initial management of vestibular schwannoma in the United States. J Clin Neurosci. 2019 Oct; 68:174-178.
Score: 0.004
-
Whitaker TJ, Mayo CS, Ma DJ, Haddock MG, Miller RC, Corbin KS, Neben-Wittich M, Leenstra JL, Laack NN, Fatyga M, Schild SE, Vargas CE, Tzou KS, Hadley AR, Buskirk SJ, Foote RL. Data collection of patient outcomes: one institution's experience. J Radiat Res. 2018 Mar 01; 59(suppl_1):i19-i24.
Score: 0.004
-
Hintenlang LL, Miller DH, Kaleem T, Patel N, May BC, Tzou KS, Vallow LA, Buskirk SJ, Miller RC, Ko SJ, Jaeckle KA, Trifiletti DM, Peterson JL. Treatment of a glioblastoma multiforme dural metastasis with stereotactic radiosurgery: A case report and select review of the literature. J Clin Neurosci. 2018 Feb; 48:118-121.
Score: 0.004
-
Robinson JL, Tzou KS, Parker AS, Heckman MG, Wu KJ, Hilton TW, Pisansky TM, Schild SE, Peterson JL, Vallow LA, Buskirk SJ. GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer. Br J Radiol. 2017 Jul; 90(1075):20170174.
Score: 0.003
-
Wong WW, Anderson EM, Mohammadi H, Daniels TB, Schild SE, Keole SR, Choo CR, Tzou KS, Bryce AH, Ho TH, Quevedo FJ, Vora SA. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):e969-e975.
Score: 0.003
-
Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, Buskirk SJ. Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. J Clin Oncol. 2016 11 10; 34(32):3864-3871.
Score: 0.003
-
Joseph RW, Cappel M, Tzou K, Bagaria S, Gilstrap C, Swaika A, Jambusaria-Pahlajani A. Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod. Melanoma Res. 2016 08; 26(4):409-12.
Score: 0.003
-
Heckman MG, Robinson JL, Tzou KS, Parker AS, Wu KJ, Hilton TW, Howat WJ, Miller JL, Kreinest PA, Pisansky TM, Schild SE, Peterson JL, Vallow LA, Carroll JS, Buskirk SJ. An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer. PLoS One. 2016; 11(3):e0151785.
Score: 0.003
-
Lee RJ, Tzou KS, Heckman MG, Hobbs CJ, Rawal B, Diehl NN, Peterson JL, Paryani NN, Ko SJ, Daugherty LC, Vallow LA, Wong W, Schild S, Pisansky TM, Buskirk SJ. Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy. BJU Int. 2016 08; 118(2):236-42.
Score: 0.003
-
Peterson JL, Buskirk SJ, Heckman MG, Diehl NN, Bernard JR, Tzou KS, Casale HE, Bellefontaine LP, Serago C, Kim S, Vallow LA, Daugherty LC, Ko SJ. Image-guided intensity-modulated radiotherapy for prostate cancer: Dose constraints for the anterior rectal wall to minimize rectal toxicity. Med Dosim. 2014; 39(1):12-7.
Score: 0.003
-
Peterson JL, Vallow LA, Johnson DW, Heckman MG, Diehl NN, Smith AA, Tzou KS, Paz-Fumagalli R, Kim S, Ko SJ, Daugherty LC, Kim GP, Brown N, Mori KW, Buskirk SJ. Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients. Brachytherapy. 2013 Nov-Dec; 12(6):573-9.
Score: 0.003
-
Clarke JW, Hadziahmetovic M, Tzou K, Lau CC, Paulino AC, Grecula JC, Montebello JF, Mayr NA, Lo SS. What is the best adjuvant treatment for very young patients with medulloblastoma? Expert Rev Neurother. 2007 Apr; 7(4):373-81.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|